title: Compound heterozygosity for the common sulfonylurea receptor mutations can cause mild diazoxide-sensitive hyperinsulinism.
abstract: Persistent hyperinsulinemic hypoglycemia of infancy (PHHI) is a disorder characterized by dysregulation of insulin secretion and prolonged hypoglycemia. Mutations in the genes of both subunits of the beta-cell KATP channel, Kir 6.2 (potassium channel) and SUR1 (sulfonylurea receptor) have been associated with the autosomal recessive form of this disorder. It was previously demonstrated that patients harboring SUR1 mutations often do not respond well to diazoxide. A patient is reported of compound heterozygosity for the 2 most common mutations previously reported to be associated with PHHI in Ashkenazi Jews; splice mutation of intron 32 (3993-9G-->A) and deletion of phenylalanine at position 1388. Relatively low glucose utilization (<10 mg/kg/min) was needed to maintain blood gllucose concentrations. In addition, treatment with diazoxide was highly effective. We suggest that diazoxide unresponsiveness is not always present in patients with SUR1 mutations and that the probable cause of the milder phenotype in this compund heterozygote state
authors: Department of Pediatrics, Sheba Medical Center, The Sackler Faculty of Medicine, Tel Aviv University, Israel.
authors: Benjamin
authors: B
authors: Dekel
authors: Daniel
authors: D
authors: Lubin
authors: Dalit
authors: D
authors: Modan-Moses
authors: Jacob
authors: J
authors: Quint
authors: Benjamin
authors: B
authors: Glaser
authors: Joseph
authors: J
authors: Meyerovitch
mesh_terms: D018528:ATP-Binding Cassette Transporters; D003981:Diazoxide / Q000627:therapeutic use*; D015180:Electrophoresis, Gel, Two-Dimensional; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006579:Heterozygote; D006801:Humans; D006946:Hyperinsulinism / Q000188:drug therapy* / Q000235:genetics*; D007223:Infant; D007231:Infant, Newborn; D007585:Jews / Q000235:genetics; D008297:Male; D009154:Mutation / Q000235:genetics*; D015221:Potassium Channels / Q000235:genetics*; D024661:Potassium Channels, Inwardly Rectifying; D011955:Receptors, Drug / Q000235:genetics*; D064233:Sulfonylurea Receptors; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: C577507:ABCC8 protein, human; D018528:ATP-Binding Cassette Transporters; D015221:Potassium Channels; D024661:Potassium Channels, Inwardly Rectifying; D011955:Receptors, Drug; D064233:Sulfonylurea Receptors; D014665:Vasodilator Agents; D003981:Diazoxide